ALAN MENTER, MD, HONORED BY ODAC AND THE JOURNAL OF DRUGS IN DERMATOLOGY

ORLANDO, Fla. (Jan. 22, 2019) – The ODAC Dermatology, Aesthetics & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD), honored dermatologist Alan Menter, MD, with the Outstanding Researcher & Educator in Psoriatic Disease Award at the conference held January 18-21 in Orlando, Fla. The award recognizes Dr. Menter’s significant contribution and lifetime commitment to the advancement of psoriatic disease research as well as his work guiding the next generation of psoriasis experts and researchers.

“Dr. Menter has dedicated his career to improving psoriasis treatment options and standards of care while also pouring countless hours into up-and-coming psoriasis experts and researchers, ensuring his legacy will continue for generations to come,” said Shelley Tanner, CEO and president of SanovaWorks, which produces the JDD and ODAC.

Bobby Mansouri, MD, became a dermatologist after serving as a research fellow under Dr. Menter and, as such, gives testimony to Dr. Menter’s impact on dermatologists and their patients.

“Dr. Menter has led the way as a champion for psoriatic disease,” said Dr. Mansouri. “It is because of people like Dr. Menter that the newest generation of dermatologists will thankfully never know the full struggle of managing psoriatic patients without targeted therapies. His dedication to psoriasis and research is one of the major reasons thousands upon thousands of patients finally have their psoriasis controlled.”

Dr. Menter is the chair of the Department of Dermatology and director of the Dermatology Residency program at Baylor University Medical Center in Dallas. In 2018, he was awarded Top Dermatologist of the Year by the International Association of Top Professionals, and in 2013, he received the Lifetime Achievement Award from the National Psoriasis Foundation. He founded the International Psoriasis Council in 2003. Dr. Menter is currently co-chair of the American Academy of Dermatology Psoriasis Guideline Work Group. He has served as an ODAC faculty member for two consecutive years.

The recipient of the Outstanding Researcher & Educator in Psoriatic Disease Award, given by the Journal of Drugs in Dermatology, is nominated and chosen through the recommendation of a panel of senior national thought-leaders in dermatology, a committee of dermatology practitioners and several industry leaders. The Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®, was founded by dermatologist Perry Robins, MD. Now in its 18th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology, presenting original articles, award-winning case reports, and timely features pertaining to new methods, techniques, and drug therapy in dermatology, which provide readers with peer-reviewed content of the utmost quality. The JDD is overseen by an International Editorial Board of more than 160 renowned experts and reaches more than 30,000 dermatology healthcare practitioners worldwide.

###